Interview: Joan Josep Berbel, Director, Invest in Catalonia
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
The Royal Academy of Medicine began its history in the first third of the eighteenth century in the midst of a gathering in the pharmacy of José Hortega, under the Enlightenment movement. In July 1733 it became a grouping of professionals, initially titled “Tertulia Médico-Chymica-Phisica” and later “Tertulia Médica Matritense”.
It received the royal sanction from Felipe V in September 18, 1734, following approval of its statutes, which became the Tertulia in Academia.
It was reorganized by Royal Decree of April 28, 1861, “to promote the progress of Spanish medicine, publish its story literature, forming the medical geography and a technological dictionary of medicine.”
It uses as emblem a shield that represents the allegory of Archimedes, which states that by using many small mirrors arranged in a dish and using the sun’s rays, set the Roman fleet on fire.
The academic medals bear a midwife allegory symbolizing medicine and the legend “Ars cum natura ad salutem conspirans”.
Today, the Royal Academy of Medicine holds public scientific sessions every Tuesday during the course, in which two scholars set scientific issues, takeover sessions, opening and closing of the course, special sessions, etc.
Regarding publications, the journal published quarterly RANM Annals, which includes the lectures delivered at scientific sessions, news bulletins, an activity newsletter and monographs, etc…
The tasks and current projects of the Royal Academy include: the Dictionary of Medical Terms, the announcement and awarding of prizes, computerization of its bibliography, etc.
It consists of fifty Academic Fellows and Honor Scholars, Corresponding National and Foreign Fees and Medals of Honor.
Its current President, since 2012, is Prof. D. Joaquin Poch Broto.
CONTACT DETAILS
Calle Arrieta nº12
28013 Madrid
Tlf.: +34 91 547 03 18
Fax: +34 91 547 03 20
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
Walther von Plettenberg, general manager of the German-Spanish Chamber of Commerce in Spain, traces the history of the organization’s activity and highlights the efforts of the Chamber in response to…
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant…
Emilio Lora-Tamayo, president of the Spanish National Research Council (CSIC), outlines Spain’s current strengths and weaknesses in the areas of research and innovation. Could you please introduce yourself to our…
Despite a number of setbacks in public funding as a result of Spain’s recession, the Spanish National Biotechnology Center (CNB) has continued to remain at the forefront of science and…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and…
The history of AmCham Spain dates back to 1917 and has a critical part of developing bilateral relations between Spain and the United States. The company’s president, Jaime Malet, discusses…
Baxter Spain’s general manager, Luigi Antoniazzi, discusses the challenges that the affiliate has faced in light of recent changes in the market, and the strategies taken to adapt to an…
Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous…
Bernardo de Rafael Topfer, Iberia Country Manager, speaks about how middle-sized companies like Orion can use niche indications to their advantage in the face of strong competition from big pharma’s…
See our Cookie Privacy Policy Here
